Olema Pharmaceuticals (NASDAQ:OLMA) Given New $58.00 Price Target at JPMorgan Chase & Co.

Olema Pharmaceuticals (NASDAQ:OLMA) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $55.00 to $58.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 304.04% from the stock’s current price.

A number of other analysts have also recently weighed in on the company. The Goldman Sachs Group lowered their price target on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. HC Wainwright lowered their target price on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Stifel Nicolaus assumed coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, February 11th. They set a “buy” rating and a $48.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $44.89.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA traded down $0.71 during trading on Wednesday, reaching $14.36. 329,800 shares of the company traded hands, compared to its average volume of 1,609,504. Olema Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $36.26. The company has a market cap of $985.61 million, a price-to-earnings ratio of -7.71 and a beta of 1.92. The stock’s 50 day moving average price is $23.81 and its two-hundred day moving average price is $18.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. As a group, analysts anticipate that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Transactions at Olema Pharmaceuticals

In other news, insider David C. Myles sold 51,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the sale, the insider owned 551,881 shares in the company, valued at approximately $16,810,295.26. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Naseem Zojwalla sold 100,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $28.04, for a total value of $2,804,000.00. Following the completion of the sale, the insider owned 53,997 shares of the company’s stock, valued at approximately $1,514,075.88. This trade represents a 64.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 805,501 shares of company stock worth $23,003,832. 16.36% of the stock is owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its position in Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after acquiring an additional 477 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Olema Pharmaceuticals by 8.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock worth $325,000 after purchasing an additional 987 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Olema Pharmaceuticals by 44.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after purchasing an additional 1,169 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Olema Pharmaceuticals by 13.8% during the fourth quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock valued at $359,000 after purchasing an additional 1,740 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Key Stories Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multiple near‑ and long‑term EPS estimates (Q1–Q4 2026 and FY2026–2030) and reiterated a Buy rating with a $38 price target — an analyst upgrade thread that supports upside expectations by trimming projected losses per share. HC Wainwright estimates (MarketBeat)
• Positive Sentiment: Citigroup raised its price target from $60 to $62 and kept a Buy rating, signaling strong bullish conviction from a major bank and providing a high‑profile bullish anchor for investors. Citigroup price‑target raise (Benzinga)
• Positive Sentiment: Recent Q4 results topped expectations and previously triggered an intraday jump (~9% noted in coverage), reinforcing the narrative that clinical/operational news can move the stock quickly. Earnings surprise drove a stock jump (Blockonomi)
• Positive Sentiment: A large $68.7M external bet reported on the company (coverage tied to its breast‑cancer program aimed at a 2027 launch) highlights significant investor interest/capital flows into Olema’s clinical story. That headline can attract momentum buyers if development milestones remain on track. Large investor bet (The Globe and Mail)
• Neutral Sentiment: Olema will present preclinical data for palazestrant and OP‑3136 at the 2026 AACR meeting — a near‑term scientific catalyst that could be stock‑moving depending on data content, but outcome uncertainty keeps this neutral until results are public. AACR presentation (Business Insider)
• Neutral Sentiment: Technical note: a recent Zacks piece flags the stock as having fallen sharply and entering oversold territory, suggesting selling pressure may be near exhaustion — a potential contrarian indicator but not a guaranteed reversal. Oversold / trend commentary (Zacks)
• Negative Sentiment: Goldman Sachs cut its price target from $38 to $27 (while keeping a Buy rating), trimming potential upside and introducing near‑term selling pressure as some investors mark positions to lower analyst targets. Goldman Sachs PT cut (Benzinga)
• Negative Sentiment: Guggenheim lowered its price target from $40 to $38 (still Buy), another downward revision that can damp momentum and contribute to intra‑day weakness when combined with profit‑taking. Guggenheim PT cut (Benzinga)

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.